Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031

Accessing in-depth insights from the ‘Acute Lymphocytic Leukemia Cell Therapy Market’ report will help you:

• Assess the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) and identify the potential countries for growth opportunities within the ALL-cell therapy market.
• Analyze the clinical and commercial landscapes of each indication, with pricing assumptions
• Evaluate indication-specific unmet needs and competitive assessments by Class of Therapy
• Identify the Likelihood of Approval Analysis for the most promising agents and Phase Transition Success Rate Analysis.
• Identify key future players based on their Pipeline Strength.

How is the ‘Acute Lymphocytic Leukemia Cell Therapy Market’ report different from other reports in the market?

• It highlights the major key regions (APAC, Europe, Middle East, and North America) in the ALL cell & gene therapies market.
• The report provides in-depth qualitative coverage of potential countries (US, France, Germany, Italy, Spain, Belgium, Canada, UK, Japan, and China) with high potential for cell and gene therapies.
• It provides deep insights into the target patient pool, clinical-stage pipeline, and autologous and allogeneic cell therapies.
• It provides information on sales forecast extrapolations, which leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.
• The report offers rich competitive intelligence content, such as competitors, needs, and opportunities which will help in making important business decisions on time.

We recommend this valuable source of information to anyone involved in:

• Pharmaceutical companies
• Biotech
• CMOs, CMOs, CDMOs
• Consulting Companies
• Professional Services (e.g., Investment, Equity Companies, Banks)

To get a snapshot of the Acute Lymphocytic Leukemia Cell Therapy market report, Download a Free Report Sample

Acute Lymphocytic Leukemia Cell Therapy Market Overview

The Acute Lymphocytic Leukemia Cell Therapy market value for the 15 markets (15M) was $2.3 billion in 2021. This included both cell therapies and established/traditional ALL therapies. The 15 markets comprise the 8 major markets and seven countries known to have increased potential for cell therapies given the current drug development landscape, namely Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada.

The Acute Lymphocytic Leukemia Cell Therapy market research report includes an assessment of the disease epidemiology and a 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) for marketed and pipeline therapies with established mechanisms of action by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for acute lymphocytic leukemia (ALL).

Acute Lymphocytic Leukemia Cell Therapy Market Drivers and Unmet Needs

Established CAR-T therapies to grow market share via label expansions: Kymriah is expected to move into 1L, and Tecartus is expected to achieve a label for the pediatric patient population. The inability to find a donor for stem cell transplants drives the need for stem cell replacement products such as NiCord and TRGFT-201.

Agents for T-ALL and infant ALL are one of the unmet needs of the ALL market. Patients with T-ALL have perhaps the highest unmet need with no biologics available. CAR-Ts present a promising strategy to overcome this unmet need. Pipeline anti-CD7 CGT and non-CGT agents are being developed to treat T-ALL patients.

To know more about the drivers in the Acute Lymphocytic Leukemia Cell Therapy Market, download a free report sample

Acute Lymphocytic Leukemia Cell Therapy Market Segmentation by Regions

The key regions in the Acute Lymphocytic Leukemia Cell Therapy market are North America, APAC, Europe, and the Middle East. North America had the highest share in 2021.

Acute Lymphocytic Leukemia Cell Therapy Market Analysis by Regions, 2021 (%)

For more regional insights on the Acute Lymphocytic Leukemia market, download a free report sample

Acute Lymphocytic Leukemia Cell Therapy Market - Competitive Landscape

Some of the future players in the Acute Lymphocytic Leukemia Cell Therapy Market are Hebei Senlang Biotechnology, Chongqing Precision Biotech, Sian Wuhan Medical Technology Co Ltd, Novartis AG, iCell Gene Therapeutics LLC, and Wugen Inc among others. Hebei Senlang Biotechnology and Chongqing Precision Biotech are the leading sponsors of cell therapy trials in the ALL market.

Acute Lymphocytic Leukemia Cell Therapy Market Report Overview

Reasons to Buy

• Obtain cell therapy sales forecasts across multiple regions

• Gain insight into promising early stage approaches

• Our indication specific forecast models answer questions such as:

• What is the target patient pool for cell & gene therapies in each cancer indication?

• Which patient groups are more likely to receive these therapies?

• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication

• What is the anticipated breakdown between autologous and allogeneic cell therapies?

• When will cell & gene therapies launch in each market?

• What is the total market value projected for the forecast end, in 2031?